A new study led by researchers at Emory University’s Rollins School of Public Health, published Monday by JAMA Network Open, estimates that nearly 20% of U.S. residents who use pre-exposure prophylaxis (PrEP) for HIV prevention—or more than 110,000 of the approximately 580,000 PrEP users nationwide in 2024—received their medication via telemedicine.
If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.
If you want to read more Like this articles, you can visit our Science category.
